# Sex Hormones and Their Receptors Regulate Liver Energy Homeostasis

**Authors:** Minqian Shen, Haifei Shi

PMC · DOI: 10.1155/2015/294278 · International Journal of Endocrinology · 2015-09-27

## TL;DR

This paper reviews how sex hormones and their receptors influence liver metabolism and energy balance, potentially offering new targets for treating fatty liver disease.

## Contribution

The paper integrates recent findings on how estrogen and androgen receptors specifically regulate lipid and glucose metabolism in the liver.

## Key findings

- Estradiol in females reduces lipogenesis and gluconeogenesis while promoting cholesterol secretion and glucose catabolism.
- Testosterone in males increases insulin receptor expression and glycogen synthesis while decreasing glucose uptake and lipogenesis.
- Sex hormone receptors are suggested as potential targets for preventing hepatic steatosis.

## Abstract

The liver is one of the most essential organs involved in the regulation of energy homeostasis. Hepatic steatosis, a major manifestation of metabolic syndrome, is associated with imbalance between lipid formation and breakdown, glucose production and catabolism, and cholesterol synthesis and secretion. Epidemiological studies show sex difference in the prevalence in fatty liver disease and suggest that sex hormones may play vital roles in regulating hepatic steatosis. In this review, we summarize current literature and discuss the role of estrogens and androgens and the mechanisms through which estrogen receptors and androgen receptors regulate lipid and glucose metabolism in the liver. In females, estradiol regulates liver metabolism via estrogen receptors by decreasing lipogenesis, gluconeogenesis, and fatty acid uptake, while enhancing lipolysis, cholesterol secretion, and glucose catabolism. In males, testosterone works via androgen receptors to increase insulin receptor expression and glycogen synthesis, decrease glucose uptake and lipogenesis, and promote cholesterol storage in the liver. These recent integrated concepts suggest that sex hormone receptors could be potential promising targets for the prevention of hepatic steatosis.

## Linked entities

- **Diseases:** fatty liver disease (MONDO:0004790), metabolic syndrome (MONDO:0000816)

## Full-text entities

- **Genes:** Ppara (peroxisome proliferator activated receptor alpha) [NCBI Gene 19013] {aka 4933429D07Rik, Nr1c1, PPAR-alpha, PPARalpha, Ppar}, Insr (insulin receptor) [NCBI Gene 16337] {aka 4932439J01Rik, CD220, D630014A15Rik, IR, IR-A, IR-B}, Cyp19a1 (cytochrome P450, family 19, subfamily a, polypeptide 1) [NCBI Gene 25147] {aka Aromatase, Cyp19, Cyp19a, p450arom}, Esr2 (estrogen receptor 2) [NCBI Gene 25149] {aka ER-beta, ERbeta, Erb2}, Srebf1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 20787] {aka ADD1, SREBP1, bHLHd1}, INSR (insulin receptor) [NCBI Gene 3643] {aka CD220, HHF5}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, Fdxr (ferredoxin reductase) [NCBI Gene 79122] {aka AR}, Gck (glucokinase) [NCBI Gene 103988] {aka GLK, Gk, Gls006, HK4, HKIV, HXKP}, Mapk1 (mitogen-activated protein kinase 1) [NCBI Gene 26413] {aka 9030612K14Rik, ERK, Erk2, MAPK2, PRKM2, Prkm1}, Lep (leptin) [NCBI Gene 25608] {aka OB, obese}, Cyp19a1 (cytochrome P450, family 19, subfamily a, polypeptide 1) [NCBI Gene 13075] {aka Ar, ArKO, Cyp19, Int-5, Int5, p450arom}, GPER1 (G protein-coupled estrogen receptor 1) [NCBI Gene 2852] {aka CEPR, CMKRL2, DRY12, FEG-1, GPCR-Br, GPER}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, PCSK9 (proprotein convertase subtilisin/kexin type 9) [NCBI Gene 255738] {aka FH3, FHCL3, HCHOLA3, LDLCQ1, NARC-1, NARC1}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, Esr2 (estrogen receptor 2 (beta)) [NCBI Gene 13983] {aka ER[b], ERbeta, Estrb}, Pparg (peroxisome proliferator-activated receptor gamma) [NCBI Gene 25664] {aka PPARgamma2}, Gper1 (G protein-coupled estrogen receptor 1) [NCBI Gene 76854] {aka 6330420K13Rik, CMKRL2, Ceprl, FEG-1, GPCR-Br, Gper}, LDLR (low density lipoprotein receptor) [NCBI Gene 3949] {aka LDLCQ2}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, Scarb1 (scavenger receptor class B, member 1) [NCBI Gene 20778] {aka CD36, Cd36l1, Chohd1, Cla-1, Cla1, D5Ertd460e}, Slc2a2 (solute carrier family 2 member 2) [NCBI Gene 25351] {aka GTT2, Glut2}, Fdxr (ferredoxin reductase) [NCBI Gene 14149] {aka AR}, ESR2 (estrogen receptor 2) [NCBI Gene 2100] {aka ER-BETA, ESR-BETA, ESRB, ESTRB, Erb, NR3A2}, Lipe (lipase E, hormone sensitive type) [NCBI Gene 25330] {aka HSL, REH}, Jun (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 16476] {aka AP-1, Junc, c-jun}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, Gcg (glucagon) [NCBI Gene 24952] {aka GLP-1, Glp1, Glp2}, Gcgr (glucagon receptor) [NCBI Gene 24953], Fasn (fatty acid synthase) [NCBI Gene 50671], Slc2a2 (solute carrier family 2 (facilitated glucose transporter), member 2) [NCBI Gene 20526] {aka Glut-2, Glut2}, Esr1 (estrogen receptor 1) [NCBI Gene 24890] {aka ER-alpha, Esr, RNESTROR}, HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) [NCBI Gene 3156] {aka LDLCQ3, LGMDR28, MYPLG}, Lpl (lipoprotein lipase) [NCBI Gene 16956], CYP19A1 (cytochrome P450 family 19 subfamily A member 1) [NCBI Gene 1588] {aka ARO, ARO1, CPV1, CYAR, CYP19, CYPXIX}, Esr1 (estrogen receptor 1 (alpha)) [NCBI Gene 13982] {aka ER, ER-alpha, ERa, ERalpha, ESR, Estr}, SLC2A2 (solute carrier family 2 member 2) [NCBI Gene 6514] {aka GLUT2}, Pgr (progesterone receptor) [NCBI Gene 25154], Gper1 (G protein-coupled estrogen receptor 1) [NCBI Gene 171104] {aka GPR41, Gper, Gpr30}, Slc2a4 (solute carrier family 2 (facilitated glucose transporter), member 4) [NCBI Gene 20528] {aka GT2, Glut-4, Glut4, twgy}, Pparg (peroxisome proliferator activated receptor gamma) [NCBI Gene 19016] {aka Nr1c3, PPAR-gamma, PPAR-gamma2, PPARgamma, PPARgamma2}, Adrb2 (adrenoceptor beta 2) [NCBI Gene 24176], SREBF1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 6720] {aka HMD, IFAP2, SREBP1, bHLHd1}, Cyp7a1 (cytochrome P450, family 7, subfamily a, polypeptide 1) [NCBI Gene 13122] {aka CYPVII, CYPVIIc}, PAK3 (p21 (RAC1) activated kinase 3) [NCBI Gene 5063] {aka ARA, MRX30, MRX47, OPHN3, PAK-3, PAK3beta}
- **Diseases:** infertility (MESH:D007246), hepatic lipid accumulation (MESH:D011017), type 2 diabetes (MESH:D003924), insulin resistance (MESH:D007333), fat (MESH:D004620), hyperandrogenism (MESH:D017588), visceral adiposity (MESH:D007418), Obesity (MESH:D009765), estrogen deficiency (MESH:D056828), hyperinsulinemic (MESH:D044903), Dyslipidemia (MESH:D050171), endocrine disorder (MESH:D004700), E2 deficiency (OMIM:613382), Hepatic steatosis (MESH:D005234), Metabolic syndrome (MESH:D024821), diseases (MESH:D004194), prostate cancer (MESH:D011471), PCOS (MESH:D011085), hyperlipidemia (MESH:D006949), intra-abdominal adiposity (MESH:D000082122), metabolic dysfunction (MESH:D008659), hyperglycemia (MESH:D006943), diabetes (MESH:D003920), hypertension (MESH:D006973), liver cancer (MESH:D006528), cardiovascular diseases (MESH:D002318), breast cancer (MESH:D001943), Androgen deficiency (MESH:D014770), hypercholesterolemia (MESH:D006937), glucose metabolic impairment (MESH:D044882), Hepatic (MESH:D056486), glucose intolerance (MESH:D018149), NAFLD (MESH:D065626)
- **Chemicals:** progesterone (MESH:D011374), bile acid (MESH:D001647), Lipid (MESH:D008055), glycogen (MESH:D006003), estriol (MESH:D004964), Metformin (MESH:D008687), Cholesterol (MESH:D002784), androstenedione (MESH:D000735), calcium (MESH:D002118), fat (MESH:D005223), E2 (MESH:D004958), Testosterone (MESH:D013739), TG (MESH:D014280), 8beta-VE2 (-), epinephrine (MESH:D004837), dehydroepiandrosterone (MESH:D003687), fatty acid (MESH:D005227), DHT (MESH:D013196), Glucose (MESH:D005947)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Mutations:** P16L
- **Cell lines:** HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC4600502/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC4600502/full.md

## References

131 references — full list in the complete paper: https://tomesphere.com/paper/PMC4600502/full.md

---
Source: https://tomesphere.com/paper/PMC4600502